Table 2.
Frequency of Peptide-specific CTLp Directed to Melan-A/Mart-127–35 Peptide in Peripheral Blood of Melanoma Patients
Patient | Frequency of CTLp to Melan-A/Mart-127–35 peptide in | ||
---|---|---|---|
PBLs | CD45RO+ T cell subset | CD45RA+ T cell subset | |
1 | 1/1,404 | ND | ND |
2 | 1/1,708 | 1/1,118 | 1/56,787 |
6 | 1/1,399 | 1/879 | <1/200,000 |
9 | 1/2,225 | ND | ND |
3 | 1/43,717 | ND | ND |
4 | 1/42,600 | ND | ND |
5 | 1/117,555 | ND | ND |
7 | <1/200,000 | <1/200,000 | 1/42,919 |
8 | 1/96,691 | <1/200,000 | 1/22,430 |
CTLp frequency was evaluated in peripheral blood by LDA as described in Materials and Methods by using peptide-loaded T2 cells as APCs. Results are expressed as peptide-specific CTL precursors/PBLs. In patients 6 and 9, frequency of Melan-A/Mart-1–specific T cells in PBLs was 1/1,456 and 1/1,843, respectively, by staining with HLA-A*0201–Melan-A/Mart-126–35 tetrameric complexes.